This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Toth, B. Search for Related Content PubMed PubMed Citation Articles by Toth, B.

The Induction of Malignant Lymphomas and Other Tumors by 7,12-Dimethylbenz(a)anthracene in the Syrian Golden Hamster¹

The Eppley Institute for Research in Cancer, University of Nebraska College of Medicine, 42nd and Dewey Avenue, Omaha, Nebraska 68105

Single and four weekly repeated intravenous injections of 7,12-dimethylbenz(a)anthracene (DMBA) in 15% fat emulsion were given to adult Syrian golden hamsters. The single DMBA treatment resulted in the induction of malignant lymphomas with an incidence of 30% in females and 25% in males, while repeated DMBA injections gave rise to incidences of 18% in females and 7% in males. In controls the corresponding figures were 2% in females and 7% in males. In addition, a number of other types of tumors were observed in the treated and control animals.

Of the twenty-five malignant lymphomas found in the treated groups, 6 were the stem-cell (undifferentiated) type, with an average latent period of 34 weeks, 8 were the lymphocytic type, with an average latent period of 46 weeks, and 11 were the histiocytic type with an average latent period of 69 weeks. Histologically, stem-cell and lymphocytic types of malignant lymphomas were nonthymic, involving the lymph nodes, spleen, liver, kidneys, and occasionally the bone marrow; the appearance of malignant lymphomas of the histiocytic types in treated as well as in controls was similar to those described in an earlier study.

The first experimental induction of malignant lymphomas in the hamster with chemical carcinogen provides a model that more closely resembles anatomically the human disease than the other previously reported rodent lymphomas.

¹ This investigation was supported by contract PH 43-68-959 from the National Cancer Institute, NIH, USPHS.

Received 10/30/68. Accepted 3/28/69.